X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x - 38.0 - View Chart
P/BV x 6.9 4.2 164.7% View Chart
Dividend Yield % 0.6 0.5 114.5%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUN PHARMA
Mar-17
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589842 188.7%   
Low Rs1,232572 215.2%   
Sales per share (Unadj.) Rs417.5131.6 317.2%  
Earnings per share (Unadj.) Rs56.332.7 172.1%  
Cash flow per share (Unadj.) Rs64.738.0 170.4%  
Dividends per share (Unadj.) Rs12.703.50 362.9%  
Dividend yield (eoy) %0.90.5 181.9%  
Book value per share (Unadj.) Rs292.9152.7 191.8%  
Shares outstanding (eoy) m119.572,399.26 5.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.4 62.9%   
Avg P/E ratio x25.121.6 115.9%  
P/CF ratio (eoy) x21.818.6 117.0%  
Price / Book Value ratio x4.84.6 104.0%  
Dividend payout %22.610.7 210.8%   
Avg Mkt Cap Rs m168,6531,696,877 9.9%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m9,17149,023 18.7%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m49,915315,784 15.8%  
Other income Rs m1,6456,232 26.4%   
Total revenues Rs m51,561322,016 16.0%   
Gross profit Rs m8,482100,893 8.4%  
Depreciation Rs m1,00612,648 8.0%   
Interest Rs m6713,998 16.8%   
Profit before tax Rs m8,45190,479 9.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60612,116 13.3%   
Profit after tax Rs m6,73178,462 8.6%  
Gross profit margin %17.031.9 53.2%  
Effective tax rate %19.013.4 141.9%   
Net profit margin %13.524.8 54.3%  
BALANCE SHEET DATA
Current assets Rs m27,062329,537 8.2%   
Current liabilities Rs m15,324178,870 8.6%   
Net working cap to sales %23.547.7 49.3%  
Current ratio x1.81.8 95.9%  
Inventory Days Days6779 84.2%  
Debtors Days Days4183 49.6%  
Net fixed assets Rs m12,610204,766 6.2%   
Share capital Rs m2392,399 10.0%   
"Free" reserves Rs m34,490363,997 9.5%   
Net worth Rs m35,027366,397 9.6%   
Long term debt Rs m1,21214,361 8.4%   
Total assets Rs m54,387614,102 8.9%  
Interest coverage x13.623.6 57.6%   
Debt to equity ratio x00 88.3%  
Sales to assets ratio x0.90.5 178.5%   
Return on assets %13.613.4 101.4%  
Return on equity %19.221.4 89.7%  
Return on capital %24.924.8 100.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56344,118 14.9%   
Fx outflow Rs m3,01224,484 12.3%   
Net fx Rs m3,55219,634 18.1%   
CASH FLOW
From Operations Rs m7,25970,822 10.2%  
From Investments Rs m1,864-42,216 -4.4%  
From Financial Activity Rs m-9,273-22,854 40.6%  
Net Cashflow Rs m-1506,107 -2.5%  

Share Holding

Indian Promoters % 66.9 63.7 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.1 645.2%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.3 -  
Shareholders   68,381 133,026 51.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NOVARTIS  TORRENT PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 18, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS